Follicular Lymphoma · line 3 · Mosunetuzumab IV step-up (8 cycles, 21-day; up to 17 if not in CR by C8) — r/r FL
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 3 |
|---|---|
| Track | aggressive |
| Linked regimen | REG-MOSUNETUZUMAB-FL |
| ID | IND-FL-3L-MOSUNETUZUMAB |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | DIS-FL |
| Sources | SRC-ESMO-LYMPHOMA-2025 SRC-NCCN-BCELL-2025 |
Notes
STUB — pending Clinical Co-Lead sign-off. Aggressive-track 3L+ bispecific for r/r FL. Glofitamab (Columvi) is alternative CD20×CD3 bispecific approved for FL by EMA (different schedule, fixed-dose obinutuzumab debulking pre-treatment) — separate future Indication / Regimen.
Used By
Algorithms
ALGO-FL-2L- ALGO-FL-2L